An Open-label, Multinational, Multicenter, Single-arm Phase Ib/II Study to Evaluate Efficacy and Safety of Oral HH2853, a Selective EZH1/2 Inhibitor, in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma
Latest Information Update: 11 Apr 2025
At a glance
- Drugs HH 2853 (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Haihe Biopharma
- 11 Apr 2025 New trial record